ClinicalTrials.gg
Not yet recruitingNCT07941180Updated Nov 17, 2026

BTK Inhibitor-Containing Bridging Therapy and CAR-T Outcomes in R/R LBCL

An observational study in Large B Cell Lymphoma, CAR T Cell Therapy and BTK Inhibitors, sponsored by The First Affiliated Hospital of Soochow University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by The First Affiliated Hospital of Soochow University · Observational

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
66
Ages
18 Years and older
Sex
All
01

Study summary

This observational study will examine outcomes of CAR-T cell therapy in adults with large B-cell lymphoma that has returned or has not responded to prior treatment. Participants will already have received bridging therapy that includes a BTK inhibitor before CAR-T cell infusion.

Researchers will compare outcomes between participants whose lymphoma responded to bridging therapy before CAR-T cell infusion and those whose lymphoma did not respond. The study will use medical records, imaging results, laboratory tests, treatment information, and follow-up data collected during usual care. It will not assign treatment, change medical care, or require extra tests or blood samples.

The study will assess lymphoma response after CAR-T cell therapy, safety, survival, and changes in routine blood markers of inflammation after CAR-T cell therapy.

02

Conditions studied

  • Large B Cell Lymphoma
  • CAR T Cell Therapy
  • BTK Inhibitors

Browse trials for

03

In context

Lymphoma, B-Cell

886 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

This study's planned enrollment of 66 is below the median of 150 across 70 observational studies indexed under Lymphoma, B-Cell.

Browse Lymphoma, B-Cell studies →

Lead sponsor

The First Affiliated Hospital of Soochow University is the lead sponsor of 264 studies on the registry; 151 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population comprises adults with relapsed or refractory large B-cell lymphoma (LBCL) who receive routine CAR-T cell therapy at a single center in China. Eligible patients receive BTK inhibitor-containing bridging therapy after leukapheresis and before lymphodepleting chemotherapy and have evaluable disease status after bridging therapy and before CAR-T cell infusion. Patients treated before ethics approval will be identified retrospectively from the center's CAR-T treatment records and routine medical records; eligible patients treated after ethics approval will be enrolled prospectively using the same criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 year.
  2. large B-cell lymphoma (LBCL) after one or more , including diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS); diffuse large B-cell lymphoma transformed from follicular lymphoma (tFL); grade 3B follicular lymphoma (FL3B); primary mediastinal large B-cell lymphoma (PMBCL); and high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (double-hit/triple-hit lymphoma, DHL/THL).
  3. Completion of CAR-T cell infusion at this center.
  4. Receipt of BTK inhibitor-containing bridging therapy after leukapheresis and before lymphodepleting chemotherapy.
  5. Documented, evaluable disease status after bridging therapy and before CAR-T cell infusion, based on imaging assessments or clinical records.
  6. Documented, evaluable disease status after bridging therapy and before CAR-T cell infusion, based on imaging assessments or clinical records.

Exclusion criteria

Exclusion Criteria:

  1. Inability to verify the specific BTK inhibitor(s) used, treatment start and stop dates, or information on combination therapy, thereby precluding confirmation of exposure to BTK inhibitorcontaining bridging therapy.
  2. Absence of disease assessment data between bridging therapy and CAR-T cell infusion, with post-bridging disease status not determinable from imaging reports or medical records.
  3. Major discrepancies in key baseline or treatment data that persist after review of medical records, imaging, and treatment documentation, precluding determination of bridging exposure or group assignment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
66 participants (estimated)
Patient registry
No

Groups and cohorts

  • Bridging Response (CR/PR)

    Participants with R/R LBCL who received BTK inhibitor-containing bridging therapy and underwent CAR-T cell infusion at this center. Based on the most recent routine disease assessment after bridging therapy and before CAR-T infusion, participants in this cohort achieved complete response (CR) or partial response (PR). Treatments were determined as part of usual clinical care and were not assigned by the study.

    Drug: BTK Inhibitor-Containing Bridging Therapy · Biological: CAR-T cell therapy

  • No Bridging Response (SD/PD)

    Participants with R/R LBCL who received BTK inhibitor-containing bridging therapy and underwent CAR-T cell infusion at this center. Based on the most recent routine disease assessment after bridging therapy and before CAR-T infusion, participants in this cohort had stable disease (SD) or progressive disease (PD). Treatments were determined as part of usual clinical care and were not assigned by the study.

    Drug: BTK Inhibitor-Containing Bridging Therapy · Biological: CAR-T cell therapy

Interventions

  • DrugBTK Inhibitor-Containing Bridging Therapy

    Bridging therapy containing a BTK inhibitor, including ibrutinib, zanubrutinib, orelabrutinib, acalabrutinib, pirtobrutinib, or another BTK inhibitor, administered after leukapheresis and before lymphodepleting chemotherapy as part of usual clinical care. Treatment selection, dose, duration, and combination therapy are determined by treating physicians and are not assigned or modified by the study.

  • BiologicalCAR-T cell therapy

    CAR-T cell therapy administered after lymphodepleting chemotherapy as part of usual clinical care. CAR-T target(s), product, dose, and infusion schedule are determined by treating physicians and clinical practice, and are not assigned or modified by the study.

06

What researchers measure

Primary outcomes

  1. Best objective response rate after CAR-T cell infusion

    The proportion of participants who achieve complete response (CR) or partial response (PR) at any time after CAR-T infusion and before first progression, death, initiation of new anti-lymphoma therapy, or last evaluable disease assessment. Participants without CR/PR before these events are classified as nonresponders; progression or death after CR/PR does not change responder status.

    Time frame: At approximately 1 and 3 months after CAR-T cell infusion and at subsequent scheduled follow-up visits through study completion.

Secondary outcomes

  1. Duration of response

    Among participants who achieve CR or PR, duration of response is measured from the date of first documented CR or PR to disease progression or death from any cause, whichever occurs first. Participants without progression or death will be censored at the last evaluable disease assessment or before initiation of subsequent anti-lymphoma therapy.

    Time frame: From first documented CR or PR to disease progression or death from any cause, whichever occurs first, assessed up to 10 years.

  2. Complete response rate at 1 month after CAR-T cell infusion

    Time frame: Approximately 1 month after CAR-T cell infusion.

  3. Best complete response rate after CAR-T cell infusion

    Time frame: At approximately 1 and 3 months after CAR-T cell infusion and at subsequent scheduled follow-up visits through study completion.

  4. Number of participants with CAR-T treatment-emergent adverse events

    The number and percentage of participants with any adverse event occurring after CAR-T cell infusion will be reported. Safety events include cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infections, prolonged cytopenia, death, and other clinically documented adverse events considered related to CAR-T cell therapy. CRS and ICANS will be graded according to ASTCT consensus criteria; other events will be collected from routine clinical, laboratory, and medical-record data.

    Time frame: From CAR-T cell infusion to last follow-up.

  5. Objective response rate at 1 month after CAR-T cell infusion

    Time frame: Approximately 1 month after CAR-T cell infusion.

  6. Objective response rate at 3 month after CAR-T cell infusion

    Time frame: Approximately 3 months after CAR-T cell infusion.

  7. Complete response rate at 3 months after CAR-T cell infusion

    Time frame: 3 months after CAR-T cell infusion

  8. Progression-free survival

    Time frame: From CAR-T infusion to first progression, death, or last follow-up.

  9. Overall survival

    Time frame: From CAR-T infusion to death from any cause or last follow-up.

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Dec 2028, 25 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2026
First posted
Nov 17, 2026
StartEst.
Nov 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07941180
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Nov 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 17, 2026
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion